摘要
目的:通过对比静脉应用托拉塞米和呋塞米,探讨托拉塞米的临床安全性及对心功能改善的影响。方法:选取40例充血性心力衰竭患者,随机分为两组,在心衰基础治疗一致的情况下,记录两组患者治疗前后平均24 h尿量增加量,观察血压、血钾、心功能分级、EF值的变化。结果:治疗前两组各参数无统计学差异;治疗7 d后,托拉塞米组尿量增加量(861.0±133.0)ml明显优于呋塞米组(591.5±130.0)ml,差异有统计学意义(P<0.05);前者低血钾发生率为10%,后者为45%,两组差异有统计学意义(P<0.05),两组治疗对血压、EF值与心功能改善影响无显著性差异。结论:托拉塞米临床应用安全有效,可明显增加尿量,其低血钾发生率较呋塞米低,对心功能有一定的改善。
Objective：To explore the clinical safety and the impact on cardiac function by intravenous injecting Torasemide and Furosemide.Methods：Forty patients were divided into two groups.By the same basic treatment of heart failure,the average increasing urine volume of 24 h before and after treatment was recorded,and blood pressure,serum potassium,New York Heart Association,EF values were observed.Results：Before treatment,there was no significant difference between two groups.After 7 days＇ treatment,urine volume（861.0±133.0） ml of Torasemide group increased significantly more than（591.5±130.0） ml of Furosemide group,there was a significant difference between two groups（P0.05）.There was no difference between two groups in Blood pressure and New York Heart Association.Conclusion：Torasemide is safe and effective in clinical applications.It can significantly increase urine volume with a lower incidence of hypokalemia than Furosemide and also makes a certain improvement in heart function.
出处
《中国医药导报》
CAS
2011年第15期78-79,共2页
China Medical Herald
